Blood test may spot deadly transplant complication earlier
NCT ID NCT04284904
First seen May 07, 2026 · Last updated Jun 20, 2026 · Updated 8 times
Summary
This completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R every two weeks for three months after transplant. The goal was to see if changes in these markers could signal aGVHD before symptoms appear, which might allow earlier treatment and better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aGVHD biomarker monitoring (blood tests for REG3, ST2, IL-6, IL-8, TNF R)
What this could lead to
If successful, this could lead to a simple blood test that helps doctors predict and catch aGVHD earlier, potentially improving treatment and survival for stem cell transplant patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. The markers may not prove reliable enough for routine use, and results may not apply to all transplant patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.